NCT04471727 - A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Biotech Hunter

Enrollment

232

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

November 3, 2027

Study Completion Date

November 3, 2027

Conditions

Small-Cell Lung CancerNeuroendocrine Carcinoma

Interventions

BIOLOGICAL

Gocatamig

IV infusion

BIOLOGICAL

Atezolizumab

IV infusion

BIOLOGICAL

Ifinatamab Deruxtecan (I-DXd)

IV infusion

Trial Locations (11)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

37203

RECRUITING

Tennessee Oncology, Nashville

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

48201

RECRUITING

Karmanos Cancer Center, Detroit

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

80045

RECRUITING

University of Colorado, Aurora

90048

RECRUITING

Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

94143

RECRUITING

University of California San Francisco, San Francisco

97213

RECRUITING

Providence, Portland

02467

RECRUITING

Dana Farber Cancer Institute, Boston